WP
LVTX

Woodline Partners’s LAVA Therapeutics LVTX Stock Holding History

Woodline Partners’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-86,904
Closed -$946K – 721
2021
Q2 		$946K Sell
86,904
-26,338
-23% -$326K 0.02% 443
2021
Q1 		$1.72M Buy
+113,242
New +$1.56M 0.04% 309

Other funds holding LVTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.78B AUM 114.03% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Woodline Partners's LVTX Position: Q3 2021 in Review

Woodline Partners sold out of LAVA Therapeutics (LVTX) in Q3 2021, closing a stake of 86,904 shares — an estimated $946K sold.

Woodline Partners first reported a position in LVTX in Q1 2021 and held it in 2 quarters. The position peaked at $1.72M in Q1 2021. 19 funds tracked by Wall St. Rank hold LVTX as of Q3 2021.

  • Woodline Partners reported no remaining LAVA Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Woodline Partners sold 86,904 LAVA Therapeutics shares in Q3 2021, an estimated $946K.
  • Woodline Partners first reported a position in LAVA Therapeutics in Q1 2021 and held it in 2 quarters.
  • Woodline Partners's LAVA Therapeutics position peaked at $1.72M in Q1 2021.
  • 19 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q3 2021.

Based on Woodline Partners's 13F filing for Q3 2021, filed 15 Nov 2021.